Christopher J Hoimes

10PUBLICATIONS
108CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 01, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.

Amanda Nizam, Charles B Nguyen, Jinju Li

|Jul 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes

|Jul 30, 2024
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.

Channing J Paller, Marianna L Zahurak, Adel Mandl

|Jan 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes

|Sep 07, 2023
Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status.

Matthew M Mirsky, Carley Mitchell, Augustine Hong

|Jun 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak

Pageof 2

Frequent Collaborators

4 joint publications

Jonathan E Rosenberg

4 joint publications

Thomas W Flaig

4 joint publications

Matthew I Milowsky

3 joint publications

Rana R McKay